RxDoctor Payments Data

Lea Dye-Blondell

Physician Assistant · Springfield, ORNPI 1720521008

Payments from drug & device makers

$1,914in general payments, 2019–2025

Across 20 payments — averaging $95.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$1K
  • Johnson & Johnson$281
  • Atricure, Inc.$142
  • Biotronik Inc.$114
  • Alnylam Pharmaceuticals Inc.$96
  • Boston Scientific$62
  • plus $43 from 3 others

What the payments were for

  • Travel & lodging$79742%
  • Food & beverage$1,10258%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,914 in reported general payments places this provider in the 90th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$39,501
Medicare patients
270
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan428$545,275
EliquisApixaban376$476,479
JardianceEmpagliflozin358$440,769
FarxigaDapagliflozin Propanediol83$78,925
Repatha SureclickEvolocumab59$42,951
XareltoRivaroxaban14$18,018
DapagliflozinDapagliflozin Propanediol21$17,135
Torsemide375$13,626
Metoprolol Succinate660$12,562
MultaqDronedarone Hcl12$8,714
Carvedilol493$6,079
Eplerenone48$4,883
Potassium Chloride155$4,831
Furosemide521$4,598
Losartan Potassium290$3,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$476,479376 claims
Johnson & JohnsonXarelto$281$18,01814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →